Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naoxintong Capsule for Hyperlipidemia and Atherosclerotic Cardio-Cerebrovascular Disease
ChiCTR2500097533Phase 4Completed
- Sponsor
- Foshan Sanshui District People's Hospital
- Start
- Feb 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of naoxintong in hyperlipidemia and atherosclerotic disease (2 arms), sponsored by Foshan Sanshui District People's Hospital. Primary endpoint: Therapeutic effect. Started Feb 2025; status: completed.
02
Drugs
naoxintong
03
Conditions
hyperlipidemiaatherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2500097533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097533.